CD8A and renal cell carcinoma: Remarkably, stimulation with this hERV antigen also induced reactive CD8 + T cells from healthy donor PBMCs, highlighting the existence of anti-tumor CD8 + T cell surveillance targeting hERV-derived antigens in RCC and their translational potential [103].